Newdel Biotech recently announced the completion of an A+ round strategic investment led by XtalPi Holdings Limited (HKG: 2228), a global leader in AI+ automation technology platforms. This investment will fuel the deep integration of Newdel Biotech’s DNA-encoded compound library (DEL) technology with XtalPi’s AI platform, aiming to accelerate the development and commercialization of innovative drug pipelines.
Accelerating Drug Discovery
The collaboration between Newdel Biotech and XtalPi will focus on advancing the DEL+AI technology platform, enhancing efficiency and success rates in early-stage drug development. This partnership is expected to significantly speed up the discovery of novel compounds and optimize the drug development process.
About Newdel Biotech
Founded in April 2021 and incubated by the Guangdong Small Molecule New Drug Innovation Center, Newdel Biotech is a clinical-stage innovative drug development company. The company has built multiple drug discovery platforms (DEL+X) and owns a compound library with over 100 billion physical entities. Its proprietary DEL live cell screening technology enables efficient screening of difficult-to-express and purify targets, expanding the range of drug targets and hit rates.-Fineline Info & Tech
Leave a Reply